Cost‐utility analysis of bevacizumab versus ranibizumab in neovascular age‐related macular degeneration using a Markov model

Journal of Evaluation in Clinical Practice 18 (2):247-255 (2012)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,897

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Cost-Benefit versus Expected Utility Acceptance Rules.Alex C. Michalos - 1970 - PSA: Proceedings of the Biennial Meeting of the Philosophy of Science Association 1970 (1):375-402.
Decision theory and health resource allocations.Ruth B. Hoppe - 1983 - Theoretical Medicine and Bioethics 4 (2):193-205.
Revealed Preference and Expected Utility.Stephen A. Clark - 2000 - Theory and Decision 49 (2):159-174.
The Limits of Rationality.Patrick Suppes - 1981 - Grazer Philosophische Studien 12 (1):85-101.
Costs and Benefits of Cost-Benefit Analysis: A Response to Bantz and MacLean.Peter Railton - 1982 - PSA: Proceedings of the Biennial Meeting of the Philosophy of Science Association 1982:261-271.
Lottery Dependent Utility: a Reexamination.Ulrich Schmidt - 2001 - Theory and Decision 50 (1):35-58.
A Process Approach to the Utility for Gambling.Marc Le Menestrel - 2001 - Theory and Decision 50 (3):249-262.
Cost analysis of the utilization of new vascular grafts.Raphael Adar & Nava Pliskin - 1980 - Theoretical Medicine and Bioethics 1 (2):213-223.
Temporally asymmetric inference in a Markov process.Elliott Sober - 1991 - Philosophy of Science 58 (3):398-410.

Analytics

Added to PP
2013-10-30

Downloads
48 (#331,393)

6 months
2 (#1,198,900)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references